Hum. Reprod. Advance Access originally published online on March 31, 2005
Human Reproduction 2005 20(7):1833-1836; doi:10.1093/humrep/dei004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Absence of hepatotoxicity after long-term, low-dose flutamide in hyperandrogenic girls and young women
1 Endocrinology Unit, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Passeig de sant Joan de Déu, 2 08950 Esplugues, Barcelona, Spain and 2 Department of Pediatrics, University of Leuven, Leuven, Belgium
3 To whom correspondence should be addressed. Email: libanez{at}hsjdbcn.org
BACKGROUND: Flutamide is a pure non-steroidal anti-androgen that may be hepatotoxic, when given in high-dose (750 mg/d). Low- to ultralow-doses (250–62.5 mg/day) have been recently explored in patients with Polycystic Ovary Syndrome (PCOS), and these lower doses were found to confer benefit on multiple PCOS markers. There is a need for evidence on the potential hepatotoxicity of low- and ultralow-dose flutamide therapy. METHODS: We assessed circulating levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) as markers of hepatotoxicity in a total of 190 hyperandrogenic girls and young women receiving low- or ultralow-dose flutamide because of established (n=150) or incipient (n=40) PCOS without obesity. Assessments were performed before start of flutamide, after 3 months, and subsequently at least twice yearly. RESULTS: AST and ALT results were normal at baseline, and they remained so on flutamide treatment, including between 3 months and last assessment, which was after a mean time of 19 months on low- or ultralow-dose flutamide (range 3–54 months). None of the AST or ALT levels at any time during flutamide treatment was 
45 U/L. CONCLUSION: We found no evidence for hepatotoxicity in 190 hyperandrogenic girls or young women receiving low- or ultralow-dose flutamide for up to 54 months. These results may represent a first step in a long process whereby the status of low- and ultralow-dose flutamide may gradually evolve from ‘absence of evidence on toxicity’ towards ‘evidence of absence of hepatic toxicity’. Ultralow-dose flutamide may become a key component within future therapies for hyperandrogenic states in girls and young women.
Key words: androgen/androgen receptor/flutamide/hepatotoxicity/PCOS
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. K Ong, F. de Zegher, A. Lopez-Bermejo, D. B Dunger, and L. Ibanez Flutamide metformin for post-menarcheal girls with preclinical ovarian androgen excess: evidence for differential response by androgen receptor genotype Eur. J. Endocrinol., November 1, 2007; 157(5): 661 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez, A. Lopez-Bermejo, L. del Rio, G. Enriquez, C. Valls, and F. de Zegher Combined Low-Dose Pioglitazone, Flutamide, and Metformin for Women with Androgen Excess J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1710 - 1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Mehta, P. J. Malcom, and R. J. Chang The Effect of Androgen Blockade on Granulosa Cell Estradiol Production after Follicle-Stimulating Hormone Stimulation in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2006; 91(9): 3503 - 3506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tevell, H. Lennernas, M. Jonsson, M. Norlin, B. Lennernas, U. Bondesson, and M. Hedeland FLUTAMIDE METABOLISM IN FOUR DIFFERENT SPECIES IN VITRO AND IDENTIFICATION OF FLUTAMIDE METABOLITES IN HUMAN PATIENT URINE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY Drug Metab. Dispos., June 1, 2006; 34(6): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez and F. de Zegher Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women Hum. Reprod. Update, May 1, 2006; 12(3): 243 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Willenberg, M. Bahlo, W. A. Scherbaum, F. de Zegher, D. B. Dunger, L. Ibanez, and R. L. Rosenfield Hirsutism. N. Engl. J. Med., April 6, 2006; 354(14): 1533 - 1535. [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ibanez, C. Valls, and F. de Zegher Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-{alpha} and the neutrophil/lymphocyte ratio Hum. Reprod., February 1, 2006; 21(2): 451 - 456. [Abstract] [Full Text] [PDF]
|
|